gliclazide has been researched along with Autoimmune Diabetes in 21 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A major advancement in therapy of type 1 diabetes mellitus (T1DM) is the discovery of new treatment which avoids and even replaces the absolute requirement for injected insulin." | 2.58 | Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. ( Al-Salami, H; Goločorbin-Kon, S; Mikov, M; Pavlović, N; Stanimirov, B; Stankov, K; Đanić, M, 2018) |
| "Gliclazide is a drug commonly used in type 2 diabetes mellitus." | 1.46 | High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. ( Al-Salami, H; Calasan, J; Golocorbin-Kon, S; Lalic-Popovic, M; Mikov, M; Milijasevic, B; Vukmirovic, S, 2017) |
| "Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D)." | 1.43 | A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. ( Al-Salami, H; Arfuso, F; Chen-Tan, N; Mathavan, S, 2016) |
| "Since chronic kidney disease due to diabetic nephropathy (DN) is becoming an ever larger health burden worldwide, more effective therapies are desperately needed." | 1.43 | Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. ( Ahmed, LA; El-Latif, HA; Hassanein, NM; Mahfoz, AM; Shoka, AA, 2016) |
| "Gliclazide (G) is an antidiabetic drug commonly used in type 2 diabetes." | 1.40 | Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. ( Al-Salami, H; Al-Sallami, HS; Arfuso, F; Chen-Tan, N; Fakhoury, M; Fang, Z; Golocorbin-Kon, S; Mikov, M; Mooranian, A; Mukkur, T; Negrulj, R, 2014) |
| " The decrease in MKC bioavailability, when administered with gliclazide, caused by probiotic treatment in healthy but not diabetic rats suggests that probiotic treatment induced MKC metabolism or impaired its absorption, only in healthy animals." | 1.38 | Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. ( Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Mathavan, S | 5 |
| Ionescu, CM | 1 |
| Kovacevic, B | 1 |
| Mikov, M | 7 |
| Golocorbin-Kon, S | 7 |
| Mooranian, A | 4 |
| Dass, CR | 1 |
| Al-Salami, H | 10 |
| Calasan, J | 1 |
| Milijasevic, B | 1 |
| Vukmirovic, S | 1 |
| Lalic-Popovic, M | 2 |
| Đanić, M | 1 |
| Pavlović, N | 1 |
| Stanimirov, B | 1 |
| Stankov, K | 1 |
| Chen-Tan, N | 5 |
| Arfuso, F | 5 |
| Proks, P | 1 |
| de Wet, H | 1 |
| Ashcroft, FM | 1 |
| Konig, M | 1 |
| Lamos, EM | 1 |
| Stein, SA | 1 |
| Davis, SN | 1 |
| Drain, P | 1 |
| Negrulj, R | 3 |
| Martinez, J | 1 |
| Sciarretta, J | 1 |
| Mukkur, TK | 1 |
| Stojancevic, M | 1 |
| Al-Sallami, HS | 2 |
| Fang, Z | 2 |
| Mukkur, T | 1 |
| Fakhoury, M | 2 |
| Aruso, F | 1 |
| Ezel, T | 1 |
| Kocyigit, Y | 1 |
| Deveci, E | 1 |
| Atamer, Y | 1 |
| Sermet, A | 1 |
| Uysal, E | 1 |
| Aktaş, A | 1 |
| Yavuz, D | 1 |
| Oei, E | 1 |
| Samad, N | 1 |
| Visser, A | 1 |
| Chowdhury, TA | 1 |
| Fan, SL | 1 |
| Mahfoz, AM | 1 |
| El-Latif, HA | 1 |
| Ahmed, LA | 1 |
| Hassanein, NM | 1 |
| Shoka, AA | 1 |
| Butt, G | 1 |
| Tucker, I | 1 |
| Fallucca, F | 1 |
| Sciullo, E | 1 |
| Maldonato, A | 1 |
| Gram, J | 2 |
| Jespersen, J | 2 |
| Kold, A | 1 |
| Larkins, RG | 1 |
| Jerums, G | 1 |
| Taft, JL | 1 |
| Godfrey, H | 1 |
| Smith, IL | 1 |
| Martin, TJ | 1 |
| Giraudo, JR | 1 |
| Fugante, M | 1 |
| Blaque Quadri, J | 1 |
| Reyes, G | 1 |
| Duran Saucedo, N | 1 |
2 reviews available for gliclazide and Autoimmune Diabetes
| Article | Year |
|---|---|
Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 1; Gliclazide; Humans; Hypoglycemic Agents; P | 2018 |
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2013 |
2 trials available for gliclazide and Autoimmune Diabetes
| Article | Year |
|---|---|
Combined therapy with insulin and sulfonylurea for the treatment of new-onset insulin-dependent diabetes mellitus.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Gliclazide; | 1996 |
Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 1988 |
17 other studies available for gliclazide and Autoimmune Diabetes
| Article | Year |
|---|---|
Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes.
Topics: Animals; Bile Acids and Salts; Capsules; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glicl | 2020 |
High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
Topics: Animals; Bile Acids and Salts; Blood Glucose; Cholic Acid; Diabetes Mellitus, Experimental; Diabetes | 2017 |
Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Capsules; Cell Line; Cell Survival; Diabetes Me | 2018 |
Molecular mechanism of sulphonylurea block of K(ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 1; Gliclazide; Human | 2013 |
ATP and sulfonylurea linkage in the K(ATP) channel solves a diabetes puzzler.
Topics: Animals; Diabetes Mellitus, Type 1; Gliclazide; Humans; KATP Channels; Potassium Channels, Inwardly | 2013 |
An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations.
Topics: Administration, Oral; Alginates; Animals; Capsules; Cholic Acid; Diabetes Mellitus, Type 1; Drug Car | 2015 |
Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study.
Topics: Alginates; Animals; Artificial Cells; Capsules; Chemistry, Pharmaceutical; Deoxycholic Acid; Diabete | 2014 |
Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment.
Topics: Alginates; Animals; Capsules; Deoxycholic Acid; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2015 |
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia | 2015 |
The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
Topics: Administration, Oral; Alginates; Capsules; Chenodeoxycholic Acid; Diabetes Mellitus, Type 1; Drug Co | 2016 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.
Topics: Alginates; Animals; Bile Acids and Salts; Blood Glucose; Capsules; Cell Survival; Diabetes Mellitus, | 2016 |
Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
Topics: Amides; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; B | 2016 |
Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Topics: Administration, Oral; Animals; Biological Availability; Blood Glucose; Chenodeoxycholic Acid; Cholic | 2012 |
Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fibrinolysis; Gliclazide; Humans; Male; | 1991 |
Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Fibrinolys | 1988 |
Plasma activity of the enzyme N-acetil-beta-glucosaminidase in healthy and diabetic subjects: effects of treatment with a sulfonylurea drug.
Topics: Acetylglucosaminidase; Adult; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 1988 |